Developer of an enzymatic DNA synthesis platform designed to facilitate genome-scale synthesis
Developer of an enzymatic DNA synthesis platform designed to facilitate genome-scale synthesis
Biotechnology📍 Paris, FranceFounded 2014
Current Valuation
$677.15M
as of 2021-Q4
PRIVATE
QL Price
$677.15M
0% vs last round
QuantLogix's current estimate for DNA Script, published 2026-09-27 — in line with the last disclosed round of $677.15M (2021-Q4).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$677.15M
2021-Q4
weight 0.04
How this price has held up
No round has priced for DNA Script since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, DNA Script, 2026-09-27 (346f3b4216ec2110).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is DNA Script going public?
No. DNA Script is private and has not filed to go public. There is no S-1 on file.
What is DNA Script's valuation in 2026?
DNA Script is valued at $677.15M as of 2021-Q4, set by its Series C ($196.71M, Oct 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has DNA Script filed an S-1?
No public S-1 is on file for DNA Script.
How much has DNA Script raised?
DNA Script has raised $298.87M in total, most recently a Series C of $196.71M in Oct 2021.
Is DNA Script publicly traded — can you buy DNA Script stock?
No. DNA Script is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for DNA Script on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2014
HQ
Paris, France
Employees
132
Total Raised
$298.87M
Last Round
Series C — $196.71M (Oct 2021)
IPO Status
private
Fundraising Status
Series C · $196.71M · 4y 11mo ago
privateTotal raised $298.87M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$196.71M
Oct 2021
—
$677.15M
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for DNA Script — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-19. Re-checked weekly.
Talent Signal
Hiring trend
▼ Hiring downtrend
-25% vs 2026-08
Open roles
3
via greenhouse
Product-build share
33%
engineering, research, product, design
Trajectory
tightening
balanced build + GTM — 33% builders vs 67% go-to-market/G&A — scaling both sides.
Open roles trending down; no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Field Application Scientist, WorldSales Executive, EuropeSpontaneous Applications
Counted from DNA Script's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
MedicalHealth CareBiotechnologyLife Science
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q4. Refreshed quarterly.